-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today (March 30), Hausen Pharmaceuticals announced that its third-generation EGFR-TKI ametinib (trade name: Amelox) is the first-line treatment for EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) A positive result was obtained in the phase 3 study, reaching the preset primary research endpoint.
Ametinib is a third-generation EGFR (epidermal growth factor receptor)-TKI (tyrosine kinase inhibitor) developed by Hausen Pharmaceuticals.
This announcement is a phase 3 clinical study aimed at evaluating the efficacy of ametinib in the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer.
According to the press release, Hausen Pharmaceuticals is currently exploring many new indications for Ametinib, including targeted combination chemotherapy, targeted anti-vascular therapy, and so on.